<h4>Introduction</h4>Liraglutide (Lrg), a novel anti-diabetic drug that mimics the endogenous glucagon-like peptide-1 to potentiate insulin secretion, is observed to be capable of partially reversing osteopenia. The gene discussed is GCG; the disease is Osteopenia.